CONNECTIVITY
INJECTION
ORAL
RESPIRATORY
SKIN
MORE
THE MAGAZINE
EVENTS
COVID-19 NEWS
EXPERT VIEWS
INTERVIEWS
COMPANIES
OUR AUTHORS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
ABOUT
Subscribe
CONNECTIVITY
INJECTION
ORAL
RESPIRATORY
SKIN
MORE
THE MAGAZINE
EVENTS
COVID-19 NEWS
EXPERT VIEWS
INTERVIEWS
COMPANIES
OUR AUTHORS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
ABOUT
SEARCH
SEARCH
advanced search
Ophthalmic Drug Delivery
54
Issue No #54
January 30th, 2015
Download PDF
Inside the magazine
OCULAR
Dr Shikha P Barman
Integral BioSystems
SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
Shikha Barman reviews approaches for delivering drugs for diseases of the back of the eye, and introduces EySite-InjecT
™
.
OCULAR
Dr Paul Ashton
EyePoint Pharmaceuticals
PSIVIDA AND OPHTHALMIC DRUG DELIVERY
Paul Ashton describes how much of the progress that has been made recently in the treatment of ophthalmic diseases can be ascribed to effective drug delivery systems, and outlines some of the delivery technologies and resulting products for which pSivida has been responsible.
OCULAR
Dr Marc Horner
ANSYS, Inc
MODELLING OCULAR DELIVERY USING COMPUTATIONAL FLUID DYNAMICS
Paul Missel and Marc Horner describe the use of computational fluid dynamics simulations to predict drug flow and temperature inside the eye, and provide examples of applications modelling.
EXPERT VIEW
Dr Paul Ashton
HUGE THERAPEUTIC ADVANCES: BIGGER DRUG DELIVERY OPPORTUNITIES
Paul Ashton gives an introduction into the current state of the ophthalmics market.
OCULAR
Dr Dieter Scherer
Novaliq
AN INTEGRATED PIPELINE OF OPHTHALMIC PRODUCTS BASED ON EYESOL™ DELIVERY TECHNOLOGY
Dieter Scherer describes two of Novaliq’s most advanced products: NovaTears
®
, a wetting agent for the ocular surface, and CyclASol
®
, a clear formulation of Cyclosporin A. Both products use Novaliq’s semifluorinated alkane technology, EyeSol
®
.
EXPERT VIEW
Dr Ilva D Rupenthal
OCULAR DRUG DELIVERY TECHNOLOGIES: EXCITING TIMES AHEAD
Ilva Rupenthal gives a sector overview of the occular drug delivery space.
OCULAR
Dr Janice Cacace
CoreRx
EXCIPIENT SELECTION FOR OPHTHALMIC OINTMENTS
Janice Cacace and Travis Webb describe the physical properties of petrolatums as they relate to the comfort and efficacy of formulations of ophthalmic ointments.
Michael O'Rourke
Graybug
COMPANY SHOWCASE: GRAYBUG
GrayBug is advancing ophthalmic therapeutics through a continuum of polymerbased drug delivery platforms and innovative products offering sustained competitive advantage.
Top
This website uses functional cookies (but not advertising cookies). View our
Privacy Policy
.
Close
Privacy & Cookies Policy
Close
Necessary
Always Enabled